Vical Phase 3 Trial of Allovectin(R) Fails to Meet Efficacy Endpoints
ATLAS will be used in conjunction with Memorial Sloan Kettering’s patient-specific cancer neoantigen sequences and blood samples from the same cancer patients. Although this research was not powered to draw firm conclusions, the analysis of T cell responses in patients receiving CPI therapy revealed a pattern indicating a greater breadth of T cell activation for responders than non-responders. To find out more about Malaria, please visit the Centers for Disease Control. COMBACTE-MAGNET ist ein hoch innovatives Programm, in dem akademische und private Partner aus ganz Europa, einschließlich AiCuris und der Medizinischen Universität Wien, zusammenarbeiten, um die Bedrohung durch antimikrobielle Resistenz von gramnegativen Bakterien weltweit zu bekämpfen. Further information on the factors and risks that could affect Genocea’s business, financial conditions and results of operations is contained in Genocea’s filings with the SEC, which are available at www.sec.gov. In fact, 1% of all cancers worldwide are associated with Epstein-Barr Virus. Higgins is currently an entrepreneur-in-residence at Polaris Venture Partners, and he previously served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals.
Recommended in News. Last positive HSV DNA copy number per episode was equivalent across groups with slightly lower values in the 75 mg arm (), highlighting that other factors contribute to late viral clearance whether or not pritelivir is given. Astellas Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. ET. The company is developing drugs for the treatment of viruses such as human cytomegalovirus (HCMV), herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. Dosing has been completed in Vical’s first-in-human Phase 1 trial of its novel antifungal, VL-2397.
Genocea’s pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. Genocea’s approach involves collecting as many of the pathogen’s proteins as can reasonably be produced in a lab, and then monitoring how human immune cells respond to each. Two main strategies to prevent HCMV infection have been adopted: anti-HCMV drug prophylaxis or pre-emptive treatment of transplant recipients who are at risk and have evidence of HCMV infection upon screening. This represented a drop from their 2012 reported sales of $2 million. coli uptake and cLLO-mediated release is a function of the proteasome since antigen expression was blockable by proteasome inhibitors but not lysosomal inhibitors. Pritelivir has a mode of action that is distinct from other antiviral agents currently in use for treatment of HSV infections (i.e., the nucleoside analogues acyclovir and its prodrug valacyclovir as well as famciclovir, the prodrug of penciclovir). Submitted questions will be screened for appropriateness and general interest.
Transaction Date Insider Name Title Buy/Sell Number of Shares Average Share Price Total Transaction Details 11/8/2016 Eric S. Pritelivir binds to a complex composed of the HSV-2 gene products of UL5, UL8 and UL52. Because as the company states “Data suggest that laboratories using existing culture methods to diagnose HSV often experience significant false negative rates, missing up to 25 percent of true positive cases. Genocea’s ATLAS platform profiled the comprehensive spectrum of actual T cell responses mounted by humans in response to their genital herpes disease to identify the antigen targets that drove protective T cell responses. No serious adverse events, Grade 4 adverse events, or adverse events of special interest related to vaccinations were observed during the study period. Topical pritelivir will be delivered via a patch placed on the volunteer. Subjects will be randomly assigned to one of three treatment arms – pritelivir 5% ointment, placebo or Zovirax(R) Cream.
The per protocol study analyses included 131 evaluable patients: 54 receiving the monovalent (gD) vaccine, 56 receiving the bivalent vaccine (gD + UL46) and 21 receiving placebo. Throughout treatment, participants collected genital swabs four times a day for testing by HSV PCR (polymerase chain reaction) assays. Safety data have been reviewed throughout the trial by an independent safety monitoring board, and no grade 4 adverse events or serious adverse events related to vaccination have been observed. Wuppertal, Germany, June 23, 2016 – AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, announced today the publication of results assessing molecular signals of drug resistance over 28 days of therapy; this was a secondary objective from a recent phase II dose finding study with pritelivir. Japan’s Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.